Known targets — ChEMBL curated mechanism
MTORPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5
The experimentally established mechanism targets of Apitolisib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA known ✓ | P42336 | 20/20 | 1.00 |
| ▸ | PIK3CD known ✓ | O00329 | 14/20 | 1.00 |
| ▸ | MTOR known ✓ | P42345 | 11/20 | 1.00 |
| ▸ | PIK3CB known ✓ | P42338 | 11/20 | 1.00 |
| ▸ | PIK3CG known ✓ | P48736 | 10/20 | 1.00 |
| ▸ | PIK3R1 known ✓ | P27986 | 1/20 | 0.56 |
| ▸ | PIK3C2A | O00443 | 1/20 | 1.00 |
| ▸ | PIK3C2B | O00750 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | PAK4 | O96013 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | FGR | P09769 | 1/20 | 1.00 |
| ▸ | FER | P16591 | 1/20 | 1.00 |
| ▸ | PRKCA | P17252 | 1/20 | 1.00 |
| ▸ | JAK1 | P23458 | 1/20 | 1.00 |
| ▸ | TEC | P42680 | 1/20 | 1.00 |
| ▸ | SYK | P43405 | 1/20 | 1.00 |
| ▸ | PRKDC | P78527 | 1/20 | 1.00 |
| ▸ | MAP3K9 | P80192 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apitolisib SCHEMBL31270275 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| Apitolisib SCHEMBL1180678 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| Apitolisib SCHEMBL466298 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| Apitolisib SCHEMBL466297 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| SCHEMBL1182231 | 0.94 | PIK3CA (1.00) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| SCHEMBL1181040 | 0.94 | PIK3CA (1.00) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| SCHEMBL1181037 | 0.94 | PIK3CA (1.00) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| SCHEMBL11985345 | 0.94 | PIK3CA (0.88) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| SCHEMBL1180941 | 0.92 | PIK3CA (0.85) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| SCHEMBL1180938 | 0.92 | PIK3CA (0.85) | PIK3CAPIK3CDMTORPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4629989-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | Freedom Biosciences, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| CN-120202190-A | Isoquinoline derivatives as protein degrading agents, E7 degrading agents, antiviral agents, tumor therapeutic agents and immunosuppressants | RDP制药股份公司 | 2025-06-24 | — | — | CN | claimed |
| EP-4548977-A2 | NOVEL ISOQUINOLINES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-05-07 | — | — | EP | claimed |
| WO-2024123935-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | FREEDOM BIOSCIENCES, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| CN-117377474-A | Isoquinoline derivatives as antiviral and antitumor agents | RDP制药股份公司 | 2024-01-09 | — | — | CN | claimed |
| CN-116390760-A | Compositions and methods for increasing sensitivity of cancer cells to alternating electric fields | 诺沃库勒有限责任公司 | 2023-07-04 | — | — | CN | claimed |
| EP-4086250-A2 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND MTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | The Regents Of The University Of Michigan (US) | 2022-11-09 | — | — | EP | claimed |
| CN-122028938-A | Pharmaceutical combination comprising an anti-CD 37 antibody maytansinoid conjugate and a BCL2 inhibitor or PI3K inhibitor | 德彪药业国际股份公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-3664808-B1 | INHIBITORS OF MEK/PI3K, JAK/MEK, JAK/PI3K/MTOR AND MEK/PI3K/MTOR BIOLOGICAL PATHWAYS AND METHODS FOR IMPROVING LYMPHATIC UPTAKE, BIOAVAILABILITY, AND SOLUBILITY OF THERAPEUTIC COMPOUNDS | UNIV MICHIGAN REGENTS (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12579642-B2 | Methods, systems, and apparatuses for quantitative analysis of heterogeneous biomarker distribution | VENTANA MEDICAL SYSTEMS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | disclosed |
| EP-4667464-A1 | AZOLYLPYRIDINE PYRIDAZINONE AMIDE AS SOS1 INHIBITOR | Cyrus Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-11389536-B2 | Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent | BioCurity Pharmaceuticals Inc. (US) | 2022-07-19 | — | — | US | disclosed |
| CN-114652728-A | Application of Apitolisib in preparation of medicine for resisting adenovirus infection | 广东龙帆生物科技有限公司 | 2022-06-24 | — | — | CN | disclosed |
| EP-3481822-B1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND MTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-114423452-A | anti-LRRC 25 compositions and methods for modulating inflammatory phenotype of myeloid cells and uses thereof | 维西欧制药公司 | 2022-04-29 | — | — | CN | disclosed |
| US-11311624-B2 | Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-04-26 | — | — | US | disclosed |
| US-11298343-B2 | Method for treating thalassemia | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2022-04-12 | — | — | US | disclosed |
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | CAMP4 THERAPEUTICS CORPORATION | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | PNPLA2, LIPC, PNLIP | PIK3CA 1695/4885PIK3CD 2620/4885MTOR 3881/4885 |
| US-11311624-B2 | Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds | MTOR, JAK2, JAK1 | PIK3CA 14/4885PIK3CD 32/4885MTOR 1/4885 |
| US-12579642-B2 | Methods, systems, and apparatuses for quantitative analysis of heterogeneous biomarker distribution | MKI67, CD63, DSP | PIK3CA 2994/4885PIK3CD 2634/4885MTOR 2392/4885 |
| US-11298343-B2 | Method for treating thalassemia | ULK1, HBZ, ULK2 | PIK3CA 3377/4885PIK3CD 1861/4885MTOR 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.